Halozyme Provides Update on German Preliminary Injunction Hearing
Halozyme issued a press release updating investors on a German preliminary injunction hearing involving Merck's subcutaneous Keytruda. The teaser indicates an earlier German decision ordering Merck to stop distributing that product was overturned.
From the press release
SAN DIEGO, Nov. 19, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) (Halozyme), today provided an update on the German preliminary injunction hearing that overturned the decision issued in December 2025, ordering Merck to refrain from distributing and offering Keytruda SC...
As published for republication. The full text is at PR Newswire.
Comments
Log in or create a free account to comment.
No comments yet.
The headline links to the original source; the summary is written by The Market Standard. Nothing here is financial advice.